{"nctId":"NCT01722331","briefTitle":"A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","startDateStruct":{"date":"2012-12-06","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":772,"armGroups":[{"label":"Tildrakizumab 200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tildrakizumab 200 mg","Drug: Matching Placebo"]},{"label":"Tildrakizumab 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tildrakizumab 100 mg","Drug: Matching Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Tildrakizumab 200 mg","Drug: Tildrakizumab 100 mg","Drug: Matching Placebo"]}],"interventions":[{"name":"Tildrakizumab 200 mg","otherNames":["MK-3222, SCH 900222"]},{"name":"Tildrakizumab 100 mg","otherNames":["MK-3222, SCH 900222"]},{"name":"Matching Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to study enrollment\n* A candidate for phototherapy or systemic therapy\n* For the extension study: must have completed Part 3 of the base study\n* For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study\n* For the extension study: must have received active tildrakizumab (MK-3222) treatment within 12 weeks prior to the end of Part 3 of the base study\n* Premenopausal female participants must agree to abstain from heterosexual activity or use a medically accepted method of contraception or use appropriate effective contraception as per local regulations or guidelines\n* If enrolled at a Japanese site, participants with psoriatic arthritis using non-steroidal anti-inflammatory drugs (NSAIDs) must be on a stable dose for at least 4 weeks prior to the first dose of study drug and must not be expected to require an increase in dose over the course of the study\n\nExclusion Criteria:\n\n* Has erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis\n* Current or history of severe psoriatic arthritis and is well-controlled on current treatment\n* Women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or who are breast feeding\n* Expected to require topical treatment, phototherapy, or systemic treatment during the trial\n* Presence of any infection\n* History of recurrent infection requiring treatment with systemic antibiotics within 2 weeks of screening\n* Previous use of tildrakizumab (MK-3222) or other IL-23/Th-17 pathway inhibitors including P40, p19, and IL-17 antagonists\n* Evidence of active or untreated latent tuberculosis (TB)\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)\n* At Japanese sites, positive test for HBs antibody and hepatitis B virus (HBV) deoxyribonucleic acid (DNA)\n* At Japanese sites, positive test for the Hepatitis B core (HBc) antibody and HBV DNA\n* For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or who are breast feeding\n* For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities\n* For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study\n* At Japanese sites, abnormal for Beta D Glucan and/or KL-6 test result(s) at the screening visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study)","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the amount of body surface for each region involved (head=0.1; upper limbs=0.2; trunk= 0.3; and lower limbs=0.4) and the degree of involvement for each body region (0=no involvement to 6=90-100% involvement). Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-75 response indicates the number of participants achieving a 75% reduction in PASI score compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null},{"groupId":"OG001","value":"63.8","spread":null},{"groupId":"OG002","value":"5.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study)","description":"The PGA is used to determine the overall severity of a participant's psoriasis lesions at a given time point. Overall lesions will be graded for thickness, erythema, and scaling on a scale from 0 to 5. The sum of the 3 scales will be divided by 3 to obtain the PGA score. PGA is assessed as: 0= Cleared, except for residual discoloration. 1= Minimal, majority of lesions have individual scores that average 1. 2 =Mild, majority of lesions have individual scores that average 2. 3= Moderate, majority of lesions have individual scores that average 3. 4= Marked, majority of lesions have individual scores that average 4. 5= Severe, majority of lesions have individual scores that average 5.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null},{"groupId":"OG001","value":"57.9","spread":null},{"groupId":"OG002","value":"7.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study)","description":"An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"74","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study)","description":"An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study)","description":"A drug-related adverse event is an adverse event that has been determined by the investigator to be related to the study drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PASI-90 Response At Week 12","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the amount of body surface for each region involved (head=0.1; upper limbs=0.2; trunk= 0.3; and lower limbs=0.4) and the degree of involvement for each body region (0=no involvement to 6=90-100% involvement). Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-90 response indicates the number of participants achieving a 90% reduction in PASI score compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"34.6","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PASI-100 Response at Week 12","description":"The PASI is a measure of the average redness, thickness, and scaliness of lesions (each graded on a 0-4 scale), weighed by the amount of body surface for each region involved (head=0.1; upper limbs=0.2; trunk= 0.3; and lower limbs=0.4) and the degree of involvement for each body region (0=no involvement to 6=90-100% involvement). Calculated PASI score ranges from 0 to 72, with higher score indicating more severe disease status. The PASI-100 response indicates the number of participants achieving a 100% reduction in PASI score compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"13.9","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Dermatology Life Quality Index (DLQI) Score","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"6.87"},{"groupId":"OG001","value":"13.9","spread":"6.68"},{"groupId":"OG002","value":"13.2","spread":"7.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Participant DLQI Score at Week 12","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life. For a change from baseline, a larger negative number correlates with a greater improvement in the DLQI score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":null},{"groupId":"OG001","value":"-9.8","spread":null},{"groupId":"OG002","value":"-2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With DLQI Score of 0 or 1 at Week 12","description":"The DLQI questionnaire consists of 10 questions, where each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"41.5","spread":null},{"groupId":"OG002","value":"5.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":308},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Psoriasis"]}}}